TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of the Compliance and Usability of the Nexus (S9) CPAP System in Sleep Disordered Breathing
Brief Summary: Obstructive sleep apnoea (OSA) is characterised by a partial or complete collapse of the upper airway during sleep. The treatment of choice for OSA is Continuous Positive Airway Pressure (CPAP). CPAP acts as a positive airway splint, delivering a fixed positive airway pressure to the upper airway via a tube and mask. Humidification is used during CPAP therapy to improve the comfort of the delivered air and to alleviate nasal dryness/congestion.

The latest design of a CPAP device, known as Nexus (S9), encompasses new features including an improved humidification system (heated tube and climate control), reduced noise, improved comfort of breathing, and a new user interface.

This study will assess whether compliance on CPAP therapy is improved on the Nexus (S9) CPAP, and will assess the usability of the Nexus (S9) CPAP


Options:
A: Arm Label: Auto Aflex; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto AFlex | Arm Label: Auto CPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto CPAP | Arm Label: CPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: CPAP | Intervention Type: DEVICE; Name: Auto AFlex; Assigned to Arm(s): Auto Aflex | Intervention Type: DEVICE; Name: Auto CPAP; Assigned to Arm(s): Auto CPAP | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): CPAP
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: constant CPAP devices | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: automatic CPAP devices | Intervention Type: DEVICE; Name: constant CPAP devices; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: automatic CPAP devices; Assigned to Arm(s): 2
C: Arm Label: Nexus (S9) CPAP device; Type: EXPERIMENTAL; Interventions: Device: CPAP Pre Nexus (S9), Device: Nexus (S9), Device: CPAP Post Nexus (S9) | Intervention Type: DEVICE; Name: CPAP Pre Nexus (S9); Assigned to Arm(s): Nexus (S9) CPAP device | Intervention Type: DEVICE; Name: Nexus (S9); Assigned to Arm(s): Nexus (S9) CPAP device | Intervention Type: DEVICE; Name: CPAP Post Nexus (S9); Assigned to Arm(s): Nexus (S9) CPAP device
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: BiPap auto with Fi Flex | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard CPAP | Intervention Type: DEVICE; Name: BiPap auto with Fi Flex; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Standard CPAP; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Developmental and Augmented Intervention for Facilitating Expressive Language
Brief Summary: This study will contrast two experimental treatment conditions by testing whether joint attention/joint engagement intervention using spoken communication (JAE-EMT) results in better outcomes than joint attention/joint engagement intervention that is instead supplemented with an individualized AAC system (JAE-AAC). Thus, the skills of joint attention/joint engagement (JAE) remain foundational to developing expressive language but the difference in the two treatments will be between whether the JAE is administered through the more traditional spoken means (EMT) or through an augmentative and alternative communication device (AAC).


Options:
A: Arm Label: P.L.A.Y. Project Intervention for Autism; Type: EXPERIMENTAL; Interventions: Behavioral: PLAY Project Intervention for Autism | Arm Label: Special Education Pre-school; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Special education pre-school | Intervention Type: BEHAVIORAL; Name: PLAY Project Intervention for Autism; Assigned to Arm(s): P.L.A.Y. Project Intervention for Autism | Intervention Type: BEHAVIORAL; Name: Special education pre-school; Assigned to Arm(s): Special Education Pre-school
B: N/A
C: Arm Label: JAE-EMT; Type: EXPERIMENTAL; Interventions: Behavioral: JAE Intervention | Arm Label: JAE-AAC; Type: EXPERIMENTAL; Interventions: Behavioral: JAE Intervention | Intervention Type: BEHAVIORAL; Name: JAE Intervention; Assigned to Arm(s): JAE-AAC, JAE-EMT
D: Arm Label: Pivotal Response Training (PRT); Type: EXPERIMENTAL; Interventions: Behavioral: Pivotal Response Training (PRT) | Arm Label: Parent Education Group (PEG); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Parent Education Group (PEG) | Intervention Type: BEHAVIORAL; Name: Pivotal Response Training (PRT); Assigned to Arm(s): Pivotal Response Training (PRT) | Intervention Type: BEHAVIORAL; Name: Parent Education Group (PEG); Assigned to Arm(s): Parent Education Group (PEG)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease
Brief Summary: The purpose of this study is to determine whether concomitant radiofrequency Maze procedure for surgical treatment of chronic atrial fibrillation with rheumatic valve disease could provide better sinus rhythm control, improved cardiac hemodynamic status and decreased thromboembolism events and to compare if biatrial is better than left atrial procedure? 150 rheumatic valve patients with chronic atrial fibrillation (AF) having concomitant valve surgery were randomized to three groups: left atrial ablation group, bi-atrial ablation group, and Amiodarone group. All patients were scheduled followed up before discharge and at 3rd, 6th and 12th postoperative months. Standard 12-lead electrocardiography (ECG), 24-hour Holter and transthoracic echocardiography were used to determine the rhythm and cardiac hemodynamic status.


Options:
A: Arm Label: left atrial RF ablation groups; Type: EXPERIMENTAL; Interventions: Procedure: Cardioblate® Surgical Ablation System | Arm Label: Bi-atrial radiofrequency ablation group; Type: EXPERIMENTAL; Interventions: Procedure: Cardioblate® Surgical Ablation System | Arm Label: Amiodarone group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Cardioblate® Surgical Ablation System; Assigned to Arm(s): Bi-atrial radiofrequency ablation group, left atrial RF ablation groups
B: Arm Label: MVS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: MVS | Arm Label: Ablation; Type: EXPERIMENTAL; Interventions: Procedure: MVS, Device: Ablation | Intervention Type: PROCEDURE; Name: MVS; Assigned to Arm(s): Ablation, MVS | Intervention Type: DEVICE; Name: Ablation; Assigned to Arm(s): Ablation
C: Arm Label: AtriCure LAA Exclusion System; Type: EXPERIMENTAL; Interventions: Device: AtriCure LAA Exclusion System | Intervention Type: DEVICE; Name: AtriCure LAA Exclusion System; Assigned to Arm(s): AtriCure LAA Exclusion System
D: Arm Label: Add-on arrhythmia surgery; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary vein isolation using microwave energy | Intervention Type: PROCEDURE; Name: Pulmonary vein isolation using microwave energy; Assigned to Arm(s): Add-on arrhythmia surgery

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination With Vinorelbine or Capecitabine in Women With ErbB2 Overexpressing Metastatic Breast Cancer
Brief Summary: This is a randomized, parallel-arm, open-label, multi-centre, Phase II study to determine the efficacy and safety of lapatinib in combination with vinorelbine or capecitabine in women with ErbB2 overexpressing metastatic breast cancer (MBC) who have received no more than one chemotherapeutic regimen in the metastatic setting.


Options:
A: Arm Label: Lapatinib + Vinorelbine; Type: EXPERIMENTAL; Interventions: Drug: Vinorelbine, Drug: Lapatinib | Arm Label: Lapatinib + Capecitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lapatinib, Drug: Capecitabine | Intervention Type: DRUG; Name: Vinorelbine; Assigned to Arm(s): Lapatinib + Vinorelbine | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): Lapatinib + Capecitabine, Lapatinib + Vinorelbine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Lapatinib + Capecitabine
B: Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A
C: Arm Label: Capecitabine 1250 mg/m2; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine | Arm Label: Everolimus 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Everolimus 10 mg + Exemestane 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Exemestane, Drug: Everolimus | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Capecitabine 1250 mg/m2 | Intervention Type: DRUG; Name: Exemestane; Assigned to Arm(s): Everolimus 10 mg + Exemestane 25 mg | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus 10 mg, Everolimus 10 mg + Exemestane 25 mg
D: Arm Label: A (experimental group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Capecitabine, Drug: Trastuzumab | Arm Label: B (control group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): A (experimental group), B (control group) | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): A (experimental group), B (control group) | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): A (experimental group) | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): A (experimental group), B (control group)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Partner Assistance in Learning and Performing Skin Self-Examination
Brief Summary: This study is a behavioral science study designed to identify aspects of the dyadic relationship that promote Skin Self-Examination (SSE) in patients at high risk of developing melanoma. The patient is randomized to receive the educational intervention either as a solo learner or with the partner.


Options:
A: Arm Label: Shared decision-making aid; Type: EXPERIMENTAL; Interventions: Other: Shared decision-making aid | Arm Label: Generic hard-copy diabetes resources; Type: PLACEBO_COMPARATOR; Interventions: Other: Generic hard copy diabetes resources, Other: Generic online diabetes resources | Intervention Type: OTHER; Name: Shared decision-making aid; Assigned to Arm(s): Shared decision-making aid | Intervention Type: OTHER; Name: Generic hard copy diabetes resources; Assigned to Arm(s): Generic hard-copy diabetes resources | Intervention Type: OTHER; Name: Generic online diabetes resources; Assigned to Arm(s): Generic hard-copy diabetes resources
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention with Colorectal Website; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Colorectal Web | Intervention Type: BEHAVIORAL; Name: Colorectal Web; Assigned to Arm(s): Intervention with Colorectal Website
C: Arm Label: Personalized Risk Information; Type: ACTIVE_COMPARATOR; Interventions: Other: Personalized Heart Attack and Stroke Risk | Arm Label: Standard Education; Type: OTHER; Interventions: Other: Standard Education | Intervention Type: OTHER; Name: Personalized Heart Attack and Stroke Risk; Assigned to Arm(s): Personalized Risk Information | Intervention Type: OTHER; Name: Standard Education; Assigned to Arm(s): Standard Education
D: Arm Label: Solo Learning; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Skin Self Examination Information and ABCDE Rule | Arm Label: Dyadic Learning; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Skin Self Examination Information and ABCDE Rule | Intervention Type: BEHAVIORAL; Name: Skin Self Examination Information and ABCDE Rule; Assigned to Arm(s): Dyadic Learning, Solo Learning

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating to Target for Patients With Hypertension
Brief Summary: Patients with poorly controlled hypertension will have improved hypertensive control with telephone coaching and with telephone coaching combined with home-titration of medications.


Options:
A: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
B: Arm Label: Health coaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health coaching | Arm Label: Health coaching plus home-titration; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching plus home titration | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): Health coaching | Intervention Type: BEHAVIORAL; Name: Health coaching plus home titration; Assigned to Arm(s): Health coaching plus home-titration
C: Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: attention control; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Peer Mentoring Intervention; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Spanish-Language Intervention to Enhance Routine HIV Patient Care Delivery [CARE+ Spanish]
Brief Summary: The purpose of this study is to see if a computer counseling tool helps Spanish-speaking people living with HIV to have safer sex and to do well on their HIV medicines.


Options:
A: Arm Label: PREPARE intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PREPARE Intervention; Assigned to Arm(s): PREPARE intervention
B: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Lifestyle intervention
C: Arm Label: Exercise Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Intervention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Wellness control | Intervention Type: BEHAVIORAL; Name: Wellness control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Physical Activity Intervention; Assigned to Arm(s): Exercise Intervention
D: Arm Label: Full CARE+ Spanish computer-counseling group; Type: ACTIVE_COMPARATOR; Interventions: Other: CARE+ Spanish computer counseling session | Arm Label: Brief risk assessment study group only (control); Type: ACTIVE_COMPARATOR; Interventions: Other: CARE+ Spanish brief computer risk assessment session | Intervention Type: OTHER; Name: CARE+ Spanish computer counseling session; Assigned to Arm(s): Full CARE+ Spanish computer-counseling group | Intervention Type: OTHER; Name: CARE+ Spanish brief computer risk assessment session; Assigned to Arm(s): Brief risk assessment study group only (control)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevalence of Chronic Airway Onstruction in a Subject Population With a History of Cigarette Smoking in a Primary Care Setting
Brief Summary: This is a cross-sectional study to determine the prevalence of symptomatic airway obstruction using the LFQ as a screening tool in primary care patients with a history of cigarette smoking and to provide descriptive data of this patient population. The study design is multicenter, cross-sectional, and involves a single visit. This study is not intended to evaluate the efficacy or safety of any investigational products. Following completion of written informed consent, eligible study subjects will complete a single study visit encompassing all required study assessments. Study subjects will not receive blinded study medication for evaluations of efficacy and safety.

All eligible patients will complete a self-administered Web survey that will include the LFQ. To meet both the primary and secondary aims, all patients with LFQ ≤ 18 (current cut-off for obstruction), as well as 5% of patients who score \> 18, will be candidates for spirometric assessment. Only this subset of patients will undergo pulmonary function tests. Albuterol will be self-administered for determination of post-bronchodilator forced expiratory volume in one-second (FEV1)/forced vital capacity (FVC) ratio and post-bronchodilator FEV1 percentage of predicted normal. The study will end when 800 patients have been assessed spirometrically or 3,000 patients have completed the LFQ (whichever criterion is achieved first).

Prior to implementation of the full study, a pilot study will be conducted at two of the chosen study sites to pretest the proposed study procedures.


Options:
A: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Tiotropium + SERETIDE 50/500; Assigned to Arm(s): N/A
C: Arm Label: Triple therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide/formoterol and tiotropium | Arm Label: Combination therapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Budesonide/formoterol and placebo | Intervention Type: DRUG; Name: Budesonide/formoterol and tiotropium; Assigned to Arm(s): Triple therapy | Intervention Type: DRUG; Name: Budesonide/formoterol and placebo; Assigned to Arm(s): Combination therapy
D: Arm Label: N/A (Survey study); Type: N/A; Interventions: Other: Non-Interventional | Intervention Type: OTHER; Name: Non-Interventional; Assigned to Arm(s): N/A (Survey study)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Recruitment Maneuver Increases Oxygenation After Intubation in Hypoxemic ICU Patients: a Randomized Controlled Study
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of a recruitment maneuver immediately after intubation in hypoxemic patients.


Options:
A: Arm Label: One Group; Type: N/A; Interventions: N/A
B: Intervention Type: OTHER; Name: Recruitment maneuver; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Control Ventilation Strategy; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Different Mechanical Ventilation Protocols | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Different Mechanical Ventilation Protocols | Intervention Type: OTHER; Name: Different Mechanical Ventilation Protocols; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipran Treatment
Brief Summary: The purpose of this study is to evaluate the durability of effect of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment and to characterize the effects of milnacipran on multiple symptoms of fibromyalgia, as demonstrated by changes in symptoms following the discontinuation of milnacipran.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran hydrochloride | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran hydrochloride; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: milnacipran hydrochloride; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipran Treatment
Brief Summary: The purpose of this study is to evaluate the durability of effect of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment and to characterize the effects of milnacipran on multiple symptoms of fibromyalgia, as demonstrated by changes in symptoms following the discontinuation of milnacipran.


Options:
A: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): 2
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D
D: Arm Label: Minalcipran 100 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 200 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg

Answer: B